Related Experiment Video
Updated: Jul 18, 2025
Viral Nanoparticles for In vivo Tumor Imaging
Published on: November 16, 2012
Targeting CXCR4-expressing Cancer Cells with Avidin-poly (lactic-co-glycolic acid) Nanoparticle Surface Modified with
Shiba Ansari1, Madeeha Mudassir2, B Vijayalekshmi3
1Department of Biochemistry, University College of Medical Sciences, Delhi, India.
Background:
Chemokine receptor CXCR4 is frequently present in cells of various cancers. Hence, targeted therapy using CXCR4 ligands, such as DV1 peptide, on drug-loaded nanoparticles, has the potential to enhance the efficiency of cancer treatment.
Aim:
The present study created a CXCR4-targeting drug delivery system using avidin-poly (lactic-co-glycolic acid) (PLGA) nanoparticle surface tagged with biotinylated DV1 peptide ligand.
Materials And Methods:
A double-emulsion solvent evaporation technique was employed to prepare avidin-PLGA nanoparticles and characterized by transmission electron microscopy (TEM) and dynamic light scattering. Uptake was studied by confocal microscopy after incorporating fluorescein isothiocyanate (FITC)-labeled albumin inside the nanoparticles during their synthesis. Peptide-biotin-avidin-PLGA nanoparticles were tested in vitro on CXCR4-expressing U87MG cells. Photomicroscopy was done by a Nikon A1 Confocal Microscope, and pictures were analyzed by Nikon NIS-Elements BR software.
Results:
Experimental results confirmed the specificity of DV1 peptide-tagged avidin-PLGA nanoparticles for cells expressing CXCR4 receptors. The avidin-PLGA nanoparticles were successfully synthesized and the same was confirmed by tagging them with FITC-labeled biotin.
Conclusion:
Avidin-PLGA nanoparticle surface tagged with biotinylated DV1 peptide ligand has potential clinical application in the treatment of various cancers as targeted therapy for CXCR4-expressing cancer cells.
Insights
This study developed targeted nanoparticles for cancer therapy. The DV1 peptide-tagged avidin-poly (lactic-co-glycolic acid) nanoparticles specifically target CXCR4-expressing cancer cells, showing potential for enhanced cancer treatment.
Area of Science:
- Biomedical Engineering
- Nanotechnology
- Oncology
Background:
- Chemokine receptor CXCR4 is a common target in various cancers.
- Targeted drug delivery systems can improve cancer treatment efficacy.
- DV1 peptide is a potential CXCR4 ligand for targeted therapy.
Purpose of the Study:
- To create a CXCR4-targeting drug delivery system using avidin-poly (lactic-co-glycolic acid) (PLGA) nanoparticles.
- To functionalize nanoparticle surfaces with a biotinylated DV1 peptide ligand.
- To evaluate the targeted delivery and specificity of the developed nanoparticles.
Main Methods:
- Avidin-PLGA nanoparticles were synthesized using a double-emulsion solvent evaporation technique.
- Nanoparticle characterization included transmission electron microscopy (TEM) and dynamic light scattering.
- In vitro studies on U87MG cells (CXCR4-expressing) were conducted using confocal microscopy.
Main Results:
- Successful synthesis of avidin-PLGA nanoparticles confirmed by FITC-labeled biotin tagging.
- DV1 peptide-tagged nanoparticles demonstrated specific uptake by CXCR4-expressing cells.
- The targeted delivery system showed specificity for cancer cells with CXCR4 receptors.
Conclusions:
- The developed avidin-PLGA nanoparticles tagged with biotinylated DV1 peptide are effective for targeted cancer therapy.
- This targeted delivery system shows promise for treating CXCR4-expressing cancers.
- The system has potential clinical applications in enhancing cancer treatment efficiency.
More Related Videos
09:12Surface Functionalization of Hepatitis E Virus Nanoparticles Using Chemical Conjugation Methods
Published on: May 11, 2018
10:18Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
Published on: July 7, 2023